SCHEMBL5367671

SCHEMBL5367671

O=C1Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc2C1=Cc1ccc(O)c(O)c1O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 4/20 0.54
MGAT2 Q10469 2/20 0.51
MAP3K7 O43318 1/20 0.49
TAB1 Q15750 1/20 0.49
TLK2 Q86UE8 2/20 0.43
PRKDC P78527 1/20 0.42
BRD4 O60885 1/20 0.42
NTRK1 P04629 2/20 0.42
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
ERAP1 Q9NZ08 1/20 0.40
MAPT P10636 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
SYK P43405 1/20 0.39
PKM P14618 1/20 0.39
PKLR P30613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358224 0.92 MOGAT2 (0.54) MOGAT2MGAT2MAP3K7TAB1TLK2
SCHEMBL7139520 0.92 MOGAT2 (0.53) MOGAT2MGAT2MAP3K7TAB1TLK2
SCHEMBL5357716 0.89 MOGAT2 (0.54) MOGAT2MGAT2TLK2PRKDCBRD4
SCHEMBL5361444 0.89 MOGAT2 (0.54) MOGAT2MGAT2TLK2PRKDCNTRK1
SCHEMBL5361507 0.88 MOGAT2 (0.55) MOGAT2MGAT2TLK2PRKDCBRD4
SCHEMBL5363040 0.87 MOGAT2 (0.52) MOGAT2MGAT2TLK2PRKDCBRD4
SCHEMBL5362152 0.87 MOGAT2 (0.52) MOGAT2MGAT2TLK2PKM
SCHEMBL5369245 0.87 MOGAT2 (0.52) MOGAT2MGAT2TLK2PRKDCNTRK1
SCHEMBL7139561 0.87 MOGAT2 (0.56) MOGAT2MGAT2TLK2PRKDCBRD4
SCHEMBL5366118 0.86 MOGAT2 (0.56) MOGAT2MGAT2TLK2PRKDCBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MGAT2 4714/4885MAP3K7 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.